Oral Solid Dosage Pharmaceutical Formulation Market Report 2026

The oral solid dosage pharmaceutical formulation market size has grown strongly in recent years. It will grow from $653.26 billion in 2025 to $692.14 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to widespread acceptance of oral drug delivery, established manufacturing infrastructure for tablets and capsules, growing prevalence of chronic diseases, cost effectiveness of oral solid dosage forms, strong regulatory familiarity with oral formulations.

The oral solid dosage pharmaceutical formulation market size is expected to see strong growth in the next few years. It will grow to $846.38 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing demand for long-acting oral medications, rising focus on patient adherence and convenience, expansion of pharmaceutical outsourcing and CDMO services, growth in global generic drug production, innovation in excipients and formulation technologies. Major trends in the forecast period include rising adoption of controlled and modified-release dosage forms, growing demand for patient-friendly oral solid formats, expansion of generic and branded solid dosage manufacturing, increasing focus on high-bioavailability formulations, shift toward cost-optimized and scalable oral dosage production.

The increasing prevalence of chronic diseases is expected to drive the growth of the oral solid dosage pharmaceutical formulation market in the coming years. Chronic diseases are long-term health conditions that last for extended periods, typically three months or longer. The rise in chronic diseases is linked to factors such as aging populations, sedentary lifestyles, unhealthy eating habits, environmental factors, and advancements in detection and diagnosis. Oral solid dosage pharmaceutical formulations are essential in managing chronic diseases and promote long-term treatment adherence due to their convenience, stability, and precise dosing. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental body, projected over 35 million new cancer cases by 2050, representing a 77% increase from the estimated 20 million cases in 2022. As a result, the growing prevalence of chronic diseases is driving the expansion of the oral solid dosage pharmaceutical formulation market.

Major companies in the Oral Solid Dosage (OSD) pharmaceutical market are focusing on developing innovative solutions such as fixed dose combinations to enhance efficacy, patient adherence, and safety. A fixed dose combination (FDC) is a medication that contains two or more active drugs within a single dosage form to simplify treatment and improve patient compliance. For instance, in February 2025, Ono Pharmaceutical Co. Ltd., a Japan-based company, received approval from the U.S. Food and Drug Administration (FDA) for Journavex (suzetrigine) 50 mg oral tablets for the management of moderate to severe acute pain in adults. The drug works by selectively inhibiting NaV1.8 sodium channels in the peripheral nervous system, blocking pain signals from reaching the brain and providing effective pain relief without the risk of addiction. Clinical trials demonstrated significant pain reduction compared to placebo, with a well-tolerated safety profile that included mild side effects such as itching and muscle spasms.

In March 2024, Roquette Frères, a France-based food company, completed the acquisition of IFF Pharma Solutions for $2.85 billion. Through this acquisition, Roquette strengthens its presence in the pharmaceutical sector, diversifies its product portfolio, enhances formulation capabilities, and expands its global reach, positioning itself as a key player in innovative drug delivery solutions. IFF Pharma Solutions is a US-based company providing pharmaceutical solutions, including tablets and capsules.

Major companies operating in the oral solid dosage pharmaceutical formulation market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc., Novartis AG, Hoffman-La-Roche Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim GmbH, Gilead Sciences, Amgen Inc., Teva Pharmaceuticals, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Biogen Inc., Lonza Group, Catalent Inc., Ashland Inc., Piramal Pharma Solutions, Jubilant Pharmova, CordenPharma International.

North America was the largest region in the oral solid dosage pharmaceutical formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral solid dosage pharmaceutical formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral solid dosage pharmaceutical formulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oral solid dosage pharmaceutical formulation market by increasing costs for imported APIs, excipients, coating materials, and specialized manufacturing equipment. These effects are more pronounced for manufacturers operating in Asia-Pacific and Europe that rely on cross-border supply chains. Higher input costs have influenced pricing and margins, particularly for generic drug producers. However, tariffs have also encouraged localization of API production, regional sourcing, and investments in domestic manufacturing capacity, strengthening supply chain resilience.

The oral solid dosage pharmaceutical formulation market research report is one of a series of new reports that provides oral solid dosage pharmaceutical formulation market statistics, including oral solid dosage pharmaceutical formulation industry global market size, regional shares, competitors with a oral solid dosage pharmaceutical formulation market share, detailed oral solid dosage pharmaceutical formulation market segments, market trends and opportunities, and any further data you may need to thrive in the oral solid dosage pharmaceutical formulation industry. This oral solid dosage pharmaceutical formulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral solid dosage pharmaceutical formulations are medications designed to be taken by mouth in a solid form. These formulations are meant to be swallowed and subsequently dissolved or dispersed in the gastrointestinal tract, enabling the active pharmaceutical ingredients (APIs) to enter the bloodstream and exert their therapeutic effects. Oral solid dosage pharmaceutical formulations play a crucial role in modern medicine, offering a reliable, convenient, and effective method of drug delivery.

The main types of oral solid dosage pharmaceutical products comprise tablets, capsules, powders and granules, lozenges and pastilles, and gummies. Tablets are solid oral dosage forms produced by compressing powdered active ingredients along with excipients into a compact, easily ingestible form. They can be formulated with various release mechanisms, including controlled release, immediate release, and delayed release. These products are made available through a variety of channels, such as hospital pharmacies, retail pharmacies, drug stores, online pharmacies, and hypermarkets or supermarkets, and are used by a diverse range of end-users, including large-sized companies, medium- and small-sized companies, and others.

The oral solid dosage pharmaceutical formulation market consists of sales of chewable tablets, multivitamin tablets, aspirin tablets, probiotic capsules, and protein powders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.